Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kodiak Sciences Inc
KOD | US
44.84
USD-0.37
-0.82%
KOD | US
Loading StockChartView...
About Kodiak Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
44.84
Open
45.89
High
45.89
Low
43.61
Kodiak Sciences Inc. a clinical stage biopharmaceutical company researches develops and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301) an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) as well as Phase III clinical study for the treatment of diabetic macular edema naïve macular edema due to retinal vein occlusion and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501 a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601 a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto California.
View LessKOD | US
Risk
268.7
Sharpe
7.28
Luna's Score
51/100
Recommendation
Hold
Luna says (KOD | US)
What's Working
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
81.4%1 month
268.7%3 months
170.6%6 months
134.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.89
Debt to equity
0.82
Debt to assets
0.44
Ent. to EBITDA
-0.12
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-192.78M
MarketCap
2.36B
MarketCap(USD)
2.36B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-71.50
Short ratio
9.18
Short perc.
4.76
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
8.47
Range1M
26.42
Range3M
26.96
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.23
Price X volume
19.24M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.12 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.89 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 170.61 | 72.80 | Riskier |
| Debt to Equity | 0.82 | -1.23 | Expensive |
| Debt to Assets | 0.44 | 0.25 | Expensive |
| Market Cap | 2.36B | 3.66B | Emerging |
